How to Prescribe Sennosides for Functional Constipation
Start with a low dose of sennosides (one 8.6 mg tablet once daily at bedtime) and titrate upward based on response, rather than beginning with the higher research doses, to minimize side effects like abdominal cramping and diarrhea. 1, 2
Initial Dosing Strategy
The 2023 AGA-ACG guidelines recommend sennosides as a first-line option for chronic idiopathic constipation, but emphasize a critical dosing consideration: the trial dose (1 g daily) is significantly higher than typical clinical practice doses 1. This matters because 83% of trial participants reduced their dose due to tolerability issues 1.
Practical Starting Doses (FDA-approved):
- Adults and children ≥12 years: Start with 2 tablets (17.2 mg sennosides) once daily at bedtime; maximum 4 tablets twice daily 2
- Children 6-11 years: Start with 1 tablet (8.6 mg) once daily; maximum 2 tablets twice daily 2
- Children 2-5 years: Start with ½ tablet (4.3 mg) once daily; maximum 1 tablet twice daily 2
Clinical pearl: Most commercially available tablets contain 8-9 mg sennosides per tablet 1. Starting lower than FDA recommendations (e.g., 1 tablet = 8.6 mg) may improve tolerability while maintaining efficacy.
Timing and Administration
- Take preferably at bedtime 2
- Onset of action: 6-12 hours 2
- This timing allows for morning bowel movements, which aligns with natural circadian patterns
Expected Efficacy
Sennosides demonstrate robust efficacy compared to placebo:
- Increased complete spontaneous bowel movements: 7.6 more per week (95% CI 5.90-9.30) 1
- Response rate: 69% vs 12% with placebo 3
- Quality of life improvement: Significant enhancement (MD 7.80,95% CI 1.40-14.20) 1
Titration Algorithm
- Week 1: Start with 1 tablet (8.6 mg) at bedtime
- Week 2: If inadequate response (fewer than 3 bowel movements/week), increase to 2 tablets (17.2 mg)
- Week 3-4: Can increase up to maximum dose if needed, but monitor closely for adverse effects
- Dose reduction: If cramping, diarrhea, or abdominal pain occurs, reduce by 50%
Duration of Treatment
- Trial duration: 4 weeks in the pivotal study 1
- Long-term use: Probably appropriate based on guideline consensus, though long-term safety data are lacking 1
- No arbitrary time limit is specified, but periodic reassessment is prudent
Common Pitfalls and How to Avoid Them
1. Starting Too High
The research dose (1 g = approximately 115 mg sennosides) caused dose reductions in 83% of participants 1. Starting at 8.6-17.2 mg prevents unnecessary side effects.
2. Abdominal Cramping and Diarrhea
These are dose-dependent 1. If they occur:
- Reduce dose by 50%
- Take with food (though not specifically studied for senna, this helps with similar agents)
- Consider alternating days rather than daily dosing
3. Antibiotic Interaction
Sennosides require gut bacteria for conversion to active metabolites (rheinanthrone and rhein) 1. Concurrent antibiotic use may reduce efficacy 1. Consider alternative laxatives during antibiotic therapy or warn patients of potential reduced effectiveness.
4. Pregnancy Concerns
Sennosides are not recommended in pregnancy due to weak genotoxic effects in animal studies, though evidence is controversial 1. Use alternative agents (e.g., osmotic laxatives) in pregnant patients.
Contraindications
Do not prescribe sennosides in patients with:
- Ileus or intestinal obstruction
- Severe dehydration
- Acute inflammatory bowel conditions 1
When to Consider Alternative Agents
If patients fail to respond to optimized sennosides dosing after 4 weeks, the guidelines suggest escalating to prescription agents like lubiprostone (24 μg twice daily) 1. However, sennosides' combination of efficacy, over-the-counter availability, and low cost makes it an attractive first-line option 1.
Monitoring
- Assess response at 1-2 weeks: Number of bowel movements per week, stool consistency (Bristol Stool Scale)
- Evaluate for adverse effects: Cramping, diarrhea, abdominal pain
- Quality of life assessment: Use validated tools if available
- Long-term users: Periodic reassessment of need and consideration of underlying causes
Combination Therapy Consideration
Adding docusate (stool softener) to sennosides does not improve efficacy and may reduce effectiveness 4. A sennosides-only protocol produced more bowel movements than sennosides plus docusate (400-600 mg/day) in hospitalized cancer patients. Avoid routine combination unless specific indication exists.